ArriVent BioPharma, Inc.
AVBPFigures shown here come from public SEC filings. Dates beside each section show the available history.
How ArriVent BioPharma, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 3 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 22, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| SECTORAL ASSET MANAGEMENT INC | 2026-03-31 | 30,013 | Not shown | SEC filing |
| Parallel Advisors, LLC | 2026-03-31 | 24 | Not shown | SEC filing |
| China Universal Asset Management Co., Ltd. | 2026-03-31 | 7,326 | Not shown | SEC filing |
| FMR LLC | 2026-03-31 | 3,016,132 | Not shown | SEC filing |
| SIGNATUREFD, LLC | 2026-03-31 | 368 | Not shown | SEC filing |
| AXQ CAPITAL, LP | 2026-03-31 | 8,935 | Not shown | SEC filing |
| Torren Management, LLC | 2026-03-31 | 33 | Not shown | SEC filing |
| Affinity Asset Advisors, LLC | 2026-03-31 | 175,000 | Not shown | SEC filing |
| NISA INVESTMENT ADVISORS, LLC | 2026-03-31 | 313 | Not shown | SEC filing |
| XTX Topco Ltd | 2026-03-31 | 63,002 | Not shown | SEC filing |
| TWO SIGMA INVESTMENTS, LP | 2026-03-31 | 48,682 | Not shown | SEC filing |
| CITADEL ADVISORS LLC | 2026-03-31 | 166,157 | Not shown | SEC filing |
| HRT FINANCIAL LP | 2026-03-31 | 47,053 | Not shown | SEC filing |
| Persistent Asset Partners Ltd | 2026-03-31 | 8,108 | Not shown | SEC filing |
| Quantinno Capital Management LP | 2026-03-31 | 30,996 | Not shown | SEC filing |
| ALLIANCEBERNSTEIN L.P. | 2026-03-31 | 28,200 | Not shown | SEC filing |
| WELLINGTON MANAGEMENT GROUP LLP | 2026-03-31 | 78,213 | Not shown | SEC filing |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2026-03-31 | 22,593 | Not shown | SEC filing |
| Bank of New York Mellon Corp | 2026-03-31 | 75,448 | Not shown | SEC filing |
| CITIGROUP INC | 2026-03-31 | 7,435 | Not shown | SEC filing |
- Each value is checked against ArriVent BioPharma, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 20 rows: no share price from within three months of their report dates is on file, so they could not be checked.
120 filers have only one report here.
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-12-10 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. · 10% owner | Common Stock | S — Open market or private sale | −555,555 | 23.37 | SEC filing |
| 2024-01-30 | HEALY JAMES · Director | Common Stock | P — Open market or private purchase | +444,444 | 18.00 | SEC filing |
| 2024-01-30 | GORDON CARL L · Director, 10% owner | Common Stock | P — Open market or private purchase | +222,222 | 18.00 | SEC filing |
| 2024-01-30 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. · 10% owner | Common Stock | P — Open market or private purchase | +555,555 | 18.00 | SEC filing |
| 2024-01-30 | ORBIMED ADVISORS LLC · Director, 10% owner | Common Stock | P — Open market or private purchase | +222,222 | 18.00 | SEC filing |
Showing 5 of 5 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-18 | Hohneker John · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +13,562 | SEC filing |
| 2026-06-18 | Parsey Merdad · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +13,562 | SEC filing |
| 2026-06-18 | Peterson Kristine · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +13,562 | SEC filing |
| 2026-06-18 | Nolet Chris · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +13,562 | SEC filing |
| 2026-02-02 | Kastenmayer James Paul · General Counsel | Stock Option (right to buy) | A — Grant, award, or other acquisition | +130,000 | SEC filing |
| 2026-02-02 | LaChapelle Robin · Chief Operating Officer | Stock Option (right to buy) | A — Grant, award, or other acquisition | +130,000 | SEC filing |
| 2026-02-02 | Kung Winston · Chief Financial Officer | Stock Option (right to buy) | A — Grant, award, or other acquisition | +140,000 | SEC filing |
| 2026-02-02 | Yao Zhengbin · President and CEO | Stock Option (right to buy) | A — Grant, award, or other acquisition | +550,000 | SEC filing |
Showing 8 of 20 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.